ABBVIE INC. CDR (REG.S) ADR

AbbVie is buying all outstanding shares of Apogee Therapeutics for $135.11 per share in cash, paying a total of $10.9 billion. The offer price represents a premium of 49.49% over Friday's closing price. The news contributed to a rise in the share prices of both companies. » More on finanzen.net

AbbVie's board of directors has declared a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to shareholders of record on July 15, 2026. The dividend yield is about 3.13%; market capitalization is stated at $383 billion. Since 2013 AbbVie has increased the dividend by more than 330% and is a member of the S&P Dividend Aristocrats Index. » More on de.investing.com

The European Commission approves the label expansion for VENCLYXTO (venetoclax) in combination with acalabrutinib (with/without obinutuzumab) and in combination with ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. The approval covers all EU member states as well as Iceland, Norway and Liechtenstein and is based on data from the phase‑3 AMPLIFY and GLOW trials and the phase‑2 CAPTIVATE study, which showed significantly reduced risks of progression or death. The all‑oral, time‑limited combinations provide additional treatment options with the potential for treatment‑free periods; common adverse events included headache, diarrhea, muscle pain, COVID‑19 and fatigue, and serious adverse events occurred in 25% of patients. VENCLYXTO is being developed by AbbVie and Roche and is already approved in over 80 countries; AbbVie reports a market capitalization of $386 billion and trailing 12‑month revenue of $62.8 billion. » More on de.investing.com